

Nelson Leung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5101091/publications.pdf>

Version: 2024-02-01

593
papers

24,667
citations

7568

77
h-index

12272

133
g-index

601
all docs

601
docs citations

601
times ranked

14302
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances, 2023, 7, 909-917.	5.2	7
2	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	1.9	9
3	Prospective evaluation of highâ€“dose methotrexate pharmacokinetics in adult patients with lymphoma usingÂnovel determinants of kidney function. Clinical and Translational Science, 2022, 15, 105-117.	3.1	7
4	A mutation in the SAA1 promoter causes hereditary amyloid A amyloidosis. Kidney International, 2022, 101, 349-359.	5.2	10
5	Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases. American Journal of Kidney Diseases, 2022, 79, 904-908.	1.9	9
6	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
7	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia, 2022, 36, 873-876.	7.2	12
8	How the amyloid fibril has unraveled: lessons for nephrology. Kidney International, 2022, 101, 663-665.	5.2	1
9	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia, 2022, 36, 1058-1065.	7.2	3
10	Characteristics and risk factors for thrombosis in <scp>POEMS</scp> syndrome: A retrospective evaluation of 230 patients. American Journal of Hematology, 2022, 97, 209-215.	4.1	5
11	The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney International, 2022, 101, 152-163.	5.2	6
12	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
13	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.8	7
14	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
15	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia, 2022, 36, 1426-1428.	7.2	7
16	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American Journal of Hematology, 2022, , .	4.1	2
17	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematology,the, 2022, 9, e143-e161.	4.6	44
18	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio â‰¥100. Leukemia, 2022, 36, 1429-1431.	7.2	8

#	ARTICLE	IF	CITATIONS
19	Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. JAMA Oncology, 2022, 8, 201.	7.1	17
20	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
21	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Advances, 2022, 6, 2763-2772.	5.2	13
22	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology: JASN, 2022, 33, 1033-1044.	6.1	47
23	A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney International Reports, 2022, 7, 1690-1693.	0.8	3
24	Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. Journal of Clinical Oncology, 2022, 40, 2447-2457.	1.6	36
25	The authors reply:. Kidney International, 2022, 101, 1086-1087.	5.2	0
26	Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. Blood Advances, 2022, , .	5.2	2
27	Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Advances, 2022, , .	5.2	1
28	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney International, 2022, 102, 382-394.	5.2	6
29	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
30	Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology, 2022, 199, 95-99.	2.5	14
31	Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Advances, 2022, 6, 5429-5435.	5.2	3
32	Heavy Chain/Light Chain Antibody Immunofluorescence to Identify Monoclonal Plasma Cells in a Case of Plasma Cell-Rich Acute Interstitial Nephritis. Kidney Medicine, 2022, 4, 100514.	2.0	0
33	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
34	Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrology Dialysis Transplantation, 2021, 36, 104-110.	0.7	12
35	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	5.2	13
36	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	2.2	4

#	ARTICLE	IF	CITATIONS
37	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	2.2	3
38	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplantation, 2021, 56, 1144-1150.	2.4	15
39	Implications of detecting serum monoclonal protein by MASSfix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
40	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	4.1	13
41	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplantation, 2021, 56, 928-935.	2.4	5
42	An extra year of Onco-Nephrology fellowship training is required for the subspecialty: PRO. Journal of Onco-Nephrology, 2021, 5, 31-34.	0.6	0
43	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leukemia and Lymphoma, 2021, 62, 316-322.	1.3	2
44	Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney International, 2021, 99, 410-420.	5.2	32
45	Systemic amyloidosis from A (AA) to T (ATTR): a review. Journal of Internal Medicine, 2021, 289, 268-292.	6.0	133
46	Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. Nephrology Dialysis Transplantation, 2021, 36, 208-215.	0.7	34
47	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	7.2	8
48	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
49	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.0	12
50	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Supportive Care in Cancer, 2021, 29, 5293-5301.	2.2	10
51	Management of acute kidney injury in symptomatic multiple myeloma. Kidney International, 2021, 99, 570-580.	5.2	31
52	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	6.1	33
53	Immunoglobulin-Negative DNAJB9-Associated Fibrillary Glomerulonephritis: A Report of 9 Cases. American Journal of Kidney Diseases, 2021, 77, 454-458.	1.9	10
54	Kidney injury and disease in patients with haematological malignancies. Nature Reviews Nephrology, 2021, 17, 386-401.	9.6	20

#	ARTICLE	IF	CITATIONS
55	Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case. <i>Kidney Medicine</i> , 2021, 3, 303-306.	2.0	2
56	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021, 96, 677-687.	3.0	16
57	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021, 11, 50.	6.2	25
58	Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. <i>Kidney International Reports</i> , 2021, 6, 857-864.	0.8	5
59	Acute Kidney Injury When Treating Periprosthetic Joint Infections After Total Knee Arthroplasties with Antibiotic-Loaded Spacers. <i>Journal of Bone and Joint Surgery - Series A</i> , 2021, 103, 754-760.	3.0	28
60	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. <i>Kidney International Reports</i> , 2021, 6, 1050-1057.	0.8	1
61	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.8	54
62	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	7.2	8
63	Evidence for Transition From Light Chain Deposition Disease by Immunofluorescence-Only to Classic Light Chain Deposition Disease. <i>Kidney International Reports</i> , 2021, 6, 1469-1474.	0.8	5
64	Monoclonal Gammopathy of Renal Significance. <i>New England Journal of Medicine</i> , 2021, 384, 1931-1941.	27.0	71
65	Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
66	Fixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e497-e502.	0.4	10
67	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32
68	Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 670-674.	2.4	13
69	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	0.4	9
70	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	1.2	3
71	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	5.2	13
72	Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases. <i>Kidney International</i> , 2021, 100, 155-170.	5.2	21

#	ARTICLE	IF	CITATIONS
73	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	1.3	2
74	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	4.1	21
75	Epstein Barr Virus-“Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. <i>Kidney International Reports</i> , 2021, 6, 2223-2227.	0.8	0
76	Hemoglobinuria in the early post stem cell transplant period: Risk factors and association with outcomes. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0002262021.	2.1	0
77	Renal Toxicity Associated With Resection and Spacer Insertion for Chronic Hip PJI. <i>Journal of Arthroplasty</i> , 2021, 36, 3289-3293.	3.1	8
78	Rituximab-Associated Flare of Cryoglobulinemic Vasculitis. <i>Kidney International Reports</i> , 2021, 6, 2840-2849.	0.8	8
79	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, 158.	6.2	9
80	Comparison of the current renal staging, progression and response criteria to predict renal survival in <sc>AL</sc> amyloidosis using a <sc>Mayo</sc> cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	4.1	8
81	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, , .	4.1	6
82	Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021, 105, 1615-1624.	1.0	0
83	177Lu-dotatate use in chronic kidney disease patients: A single center experience. <i>Journal of Onco-Nephrology</i> , 2021, 5, 162-171.	0.6	4
84	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021, 138, 2707-2707.	1.4	0
85	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN γ -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	1.4	0
86	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	1.4	0
87	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥ 100 . <i>Blood</i> , 2021, 138, 1617-1617.	1.4	0
88	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021, 138, 819-819.	1.4	1
89	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021, 138, 3805-3805.	1.4	0
90	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	6.2	8

#	ARTICLE	IF	CITATIONS
91	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. Blood, 2021, 138, 3760-3760.	1.4	1
92	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. Blood, 2021, 138, 3773-3773.	1.4	0
93	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
94	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
95	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. Blood, 2021, 138, 3761-3761.	1.4	0
96	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. Blood, 2021, 138, 1632-1632.	1.4	0
97	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. Blood, 2021, 138, 1619-1619.	1.4	0
98	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. Blood, 2021, 138, 543-543.	1.4	0
99	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. Blood, 2021, 138, 1630-1630.	1.4	0
100	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2021, 138, 119-119.	1.4	0
101	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. Blood, 2021, 138, 2650-2650.	1.4	0
102	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma” the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	6.2	28
103	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
104	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. Kidney International, 2020, 97, 589-601.	5.2	32
105	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
106	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American Journal of Hematology, 2020, 95, 4-9.	4.1	14
107	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 53-56.	0.4	8
108	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37

#	ARTICLE	IF	CITATIONS
109	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. American Journal of Hematology, 2020, 95, E60-E62.	4.1	4
110	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
111	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
112	Revisiting complete response in light chain amyloidosis. Leukemia, 2020, 34, 1472-1475.	7.2	15
113	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
114	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. Cancer Medicine, 2020, 9, 8895-8901.	2.8	3
115	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
116	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
117	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. American Journal of Hematology, 2020, 95, 1280-1287.	4.1	17
118	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
119	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2400-2411.	6.1	33
120	Immune Check Point Inhibitor-Associated Endothelialitis. Kidney International Reports, 2020, 5, 1371-1374.	0.8	6
121	Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis. Cancer, 2020, 126, 4780-4787.	4.1	19
122	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59
123	Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1069-1079.	2.2	3
124	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer Journal, 2020, 10, 124.	6.2	12
125	Perspectives From an Onconeurology Interest Group: Conference Report. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812096258.	1.1	1
126	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplantation, 2020, 55, 2132-2137.	2.4	8

#	ARTICLE	IF	CITATIONS
127	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. Blood Cancer Journal, 2020, 10, 52.	6.2	8
128	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer Journal, 2020, 10, 55.	6.2	36
129	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood, 2020, 135, 1833-1846.	1.4	42
130	Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e488-e491.	0.4	3
131	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. Mayo Clinic Proceedings, 2020, 95, 944-954.	3.0	7
132	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplantation, 2020, 55, 1297-1304.	2.4	5
133	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
134	Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study. Blood Cancer Journal, 2020, 10, 28.	6.2	31
135	Kidney transplant in multiple myeloma, the challenges, and potentials. Journal of Onco-Nephrology, 2020, 4, 15-17.	0.6	1
136	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
137	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer Journal, 2020, 10, 20.	6.2	26
138	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18
139	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. American Journal of Hematology, 2020, 95, 497-502.	4.1	35
140	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 596-601.	0.4	15
141	DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney International, 2020, 98, 498-504.	5.2	24
142	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Advances, 2020, 4, 322-326.	5.2	8
143	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 2020, 10, 41.	6.2	24
144	Renal Expression of Light Chain Binding Proteins. Frontiers in Medicine, 2020, 7, 609582.	2.6	2

#	ARTICLE	IF	CITATIONS
145	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	5.2	7
146	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 500-510.	1.9	13
147	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2383-2388.	1.3	15
148	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	1.4	2
149	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 36-37.	1.4	4
150	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 30-31.	1.4	4
151	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	1.4	1
152	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 12-13.	1.4	3
153	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	5.2	20
154	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
155	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
156	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
157	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
158	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
159	A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
160	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
161	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
162	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. <i>Blood</i> , 2020, 136, 33-34.	1.4	0

#	ARTICLE	IF	CITATIONS
163	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). Blood, 2020, 136, 21-22.	1.4	0
164	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. Blood, 2020, 136, 12-13.	1.4	0
165	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. Blood, 2020, 136, 31-32.	1.4	1
166	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. Blood, 2020, 136, 37-38.	1.4	0
167	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. American Journal of Hematology, 2019, 94, 306-311.	4.1	18
168	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplantation, 2019, 54, 442-447.	2.4	7
169	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
170	Dysproteinemia and the Kidney: Core Curriculum 2019. American Journal of Kidney Diseases, 2019, 74, 822-836.	1.9	47
171	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
172	Postsurgical thrombotic microangiopathy: Case series and review of the literature. European Journal of Haematology, 2019, 103, 307-318.	2.2	7
173	The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney International, 2019, 96, 1005-1009.	5.2	30
174	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 101-102.	3.0	9
175	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Advances, 2019, 3, 1226-1229.	5.2	7
176	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer, 2019, 125, 3574-3581.	4.1	7
177	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. American Journal of Hematology, 2019, 94, 1020-1026.	4.1	36
178	Monoclonal gammopathy-associated thrombotic microangiopathy. American Journal of Hematology, 2019, 94, E250-E253.	4.1	29
179	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	27.0	324
180	Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leukemia and Lymphoma, 2019, 60, 2271-2277.	1.3	8

#	ARTICLE	IF	CITATIONS
181	Crystalglobulin-Induced Nephropathy: Unusual Presentation in a Patient With Seronegative Rheumatoid Arthritis and Leukocytoclastic Vasculitis. <i>Kidney International Reports</i> , 2019, 4, 1190-1193.	0.8	3
182	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019, 33, 811-814.	7.2	22
183	Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity. <i>International Journal of Nephrology</i> , 2019, 2019, 1-8.	1.3	20
184	DSMA Renal Scan in Cardiac Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 936-938.	3.0	0
185	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	1.3	4
186	A case of multiple myeloma presenting with uric acid kidney stones. <i>Journal of Onco-Nephrology</i> , 2019, 3, 98-102.	0.6	0
187	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	2.5	17
188	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	6.2	38
189	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, 30.	6.2	48
190	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019, 54, 1775-1779.	2.4	9
191	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	4.1	15
192	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. <i>American Journal of Kidney Diseases</i> , 2019, 74, 276-280.	1.9	16
193	Substratification of patients with newly diagnosed standard-risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	2.5	12
194	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	7.2	7
195	Light Chain Deposition Disease. , 2019, , 597-615.		0
196	Myeloma-Associated Glomerular Disease. , 2019, , 617-631.		0
197	Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. <i>Kidney International</i> , 2019, 95, 1269-1272.	5.2	26
198	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, E141-E143.	4.1	17

#	ARTICLE	IF	CITATIONS
199	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	7.2	12
200	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€“Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, 94, 472-483.	3.0	59
201	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	5.2	41
202	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 744-750.	5.2	28
203	Recurrent Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allografts Treated With Anti-CD20 Antibodies. <i>Transplantation</i> , 2019, 103, 1477-1485.	1.0	16
204	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€“parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	4.1	11
205	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e108-e111.	2.0	20
206	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1077-1081.	2.4	7
207	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	7.2	20
208	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	9.6	330
209	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019, 33, 527-531.	7.2	36
210	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019, 33, 531-536.	7.2	72
211	Myeloma light chain cast nephropathy, a review. <i>Journal of Nephrology</i> , 2019, 32, 189-198.	2.0	39
212	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2019, 134, 72-72.	1.4	2
213	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019, 134, 4334-4334.	1.4	1
214	A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome. <i>Blood</i> , 2019, 134, 1846-1846.	1.4	2
215	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 4386-4386.	1.4	2
216	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 864-864.	1.4	13

#	ARTICLE	IF	CITATIONS
217	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). Blood, 2019, 134, 5523-5523.	1.4	0
218	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 4396-4396.	1.4	0
219	Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes. Blood, 2019, 134, 1628-1628.	1.4	0
220	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 5833-5833.	1.4	0
221	Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate. Blood, 2019, 134, 1621-1621.	1.4	0
222	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
223	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 2197-2197.	1.4	0
224	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. Blood, 2019, 134, 5490-5490.	1.4	1
225	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
226	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
227	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica, 2018, 103, 1229-1234.	3.5	10
228	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	4.1	14
229	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	2.0	21
230	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
231	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
232	Animal models of monoclonal immunoglobulin-related renal diseases. Nature Reviews Nephrology, 2018, 14, 246-264.	9.6	43
233	Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica, 2018, 103, e135-e137.	3.5	52
234	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 2018, 53, 326-333.	2.4	4

#	ARTICLE	IF	CITATIONS
235	Clinical Manifestations and Outcomes of Fluoroquinolone-Related Acute Interstitial Nephritis. Mayo Clinic Proceedings, 2018, 93, 25-31.	3.0	13
236	Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney International, 2018, 94, 159-169.	5.2	49
237	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. British Journal of Haematology, 2018, 182, 71-77.	2.5	15
238	Cisplatin nephrotoxicity: a review of the literature. Journal of Nephrology, 2018, 31, 15-25.	2.0	437
239	Natural history of t(11;14) multiple myeloma. Leukemia, 2018, 32, 131-138.	7.2	67
240	Urinalysis for the diagnosis of glomerulonephritis: role of dysmorphic red blood cells. Nephrology Dialysis Transplantation, 2018, 33, 1397-1403.	0.7	23
241	OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS. Retina, 2018, 38, 1371-1376.	1.7	31
242	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
243	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
244	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). American Journal of Hematology, 2018, 93, 17-22.	4.1	11
245	Pomalidomide+dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia, 2018, 32, 719-728.	7.2	13
246	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia, 2018, 32, 712-718.	7.2	27
247	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.8	109
248	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia, 2018, 32, 729-735.	7.2	44
249	Dysproteinemias and Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 128-139.	4.5	48
250	Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury. Kidney International Reports, 2018, 3, 337-342.	0.8	30
251	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 155-161.	2.4	8
252	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer Journal, 2018, 8, 106.	6.2	16

#	ARTICLE	IF	CITATIONS
253	Bilateral Sustained Nephrograms After Parenteral Administration of Iodinated Contrast Material: A Potential Biomarker for Acute Kidney Injury, Dialysis, and Mortality. Mayo Clinic Proceedings, 2018, 93, 867-876.	3.0	3
254	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
255	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29
256	Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogenic Stem Cell Transplant Recipient. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2018, 2, 387-391.	2.4	3
257	Utility and prognostic value of ¹⁸ F- β FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 1518-1523.	4.1	19
258	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances, 2018, 2, 769-776.	5.2	23
259	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2018, 2, 3149-3154.	5.2	23
260	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 2360-2364.	2.0	14
261	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biology of Blood and Marrow Transplantation, 2018, 24, 2157-2159.	2.0	8
262	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
263	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
264	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018, 132, 1478-1485.	1.4	173
265	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
266	Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney—What We Know and What the Future May Hold. Current Hematologic Malignancy Reports, 2018, 13, 220-226.	2.3	14
267	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
268	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
269	Use of synthetic adrenocorticotrophic hormone in patients with IgA nephropathy. BMC Nephrology, 2018, 19, 118.	1.8	5
270	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	4.5	46

#	ARTICLE	IF	CITATIONS
271	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
272	Congophilic Fibrillary Glomerulonephritis: A Case Series. American Journal of Kidney Diseases, 2018, 72, 325-336.	1.9	55
273	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 304-304.	1.4	10
274	High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. Clinical Nephrology, 2018, 89, 291-299.	0.7	3
275	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3159-3159.	1.4	0
276	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 3158-3158.	1.4	0
277	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. Blood, 2018, 132, 3226-3226.	1.4	0
278	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. Blood, 2018, 132, 1606-1606.	1.4	1
279	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. Blood, 2018, 132, 4497-4497.	1.4	0
280	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). Blood, 2018, 132, 4502-4502.	1.4	0
281	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. Blood, 2018, 132, 1902-1902.	1.4	1
282	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. Blood, 2018, 132, 5610-5610.	1.4	0
283	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
284	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2018, 132, 4615-4615.	1.4	0
285	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. Blood, 2018, 132, 719-719.	1.4	1
286	Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. Leukemia and Lymphoma, 2017, 58, 457-460.	1.3	3
287	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. Journal of the American Society of Nephrology: JASN, 2017, 28, 439-445.	6.1	57
288	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia, 2017, 31, 92-99.	7.2	30

#	ARTICLE	IF	CITATIONS
289	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 308-315.	1.3	16
290	Detection of <scp>ALECT</scp>2 amyloidosis by positron emission tomographyâ€“computed tomography imaging with florbetapir. <i>British Journal of Haematology</i> , 2017, 177, 12-12.	2.5	6
291	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 598-605.	2.0	47
292	Cystatin Câ€“Guided Vancomycin Dosing in Critically Ill Patients: AÂ“Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2017, 69, 658-666.	1.9	60
293	Ixazomibâ€“induced thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2017, 92, E53-E55.	4.1	18
294	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	3.8	45
295	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	6.2	39
296	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	4.1	16
297	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	1.4	50
298	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	1.4	249
299	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017, 52, 1126-1132.	2.4	30
300	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	3.0	4
301	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 44-45.	3.0	1
302	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	6.0	15
303	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e22-e25.	3.5	11
304	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017, 31, 1562-1569.	7.2	92
305	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e569-e569.	6.2	8
306	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, E507-E512.	4.1	5

#	ARTICLE	IF	CITATIONS
307	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	4.1	75
308	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
309	Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept. American Journal of Hematology, 2017, 92, 536-541.	4.1	16
310	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. American Journal of Hematology, 2017, 92, 549-554.	4.1	24
311	Tackling another MGRS-related kidney disease. Blood, 2017, 129, 1405-1406.	1.4	0
312	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
313	Delineation of the timing of second-line therapy post autologous stem cell transplant in patients with AL amyloidosis. Blood, 2017, 130, 1578-1584.	1.4	21
314	Ocular Manifestations of Familial Transthyretin Amyloidosis. American Journal of Ophthalmology, 2017, 183, 156-162.	3.3	64
315	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer Journal, 2017, 7, e600-e600.	6.2	57
316	Elevation of serum lactate dehydrogenase in <sc>AL</sc> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
317	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica, 2017, 102, 1439-1445.	3.5	29
318	Complex <i>p.T88N/W130R</i> mutation in the lysozyme gene leading to hereditary lysozyme amyloidosis with biopsy-proven cardiac involvement. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	3.0	4
319	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
320	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
321	CKD stage V in AL amyloidosis: is it too late to treat? Maybe not. Kidney International, 2017, 92, 1321-1322.	5.2	0
322	Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatology International, 2017, 11, 384-389.	4.2	11
323	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 183-188.	3.0	4
324	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54

#	ARTICLE	IF	CITATIONS
325	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	6.1	174
326	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 2017, 52, 34-40.	2.4	30
327	Natural history of amyloidosis isolated to fat and bone marrow aspirate. British Journal of Haematology, 2017, 179, 170-172.	2.5	10
328	Renal Disease Associated with Monoclonal Gammopathy. , 2017, , 163-194.		0
329	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41
330	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia, 2017, 31, 130-135.	7.2	63
331	Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia, 2017, 31, 123-129.	7.2	52
332	My Patient with Monoclonal Gammopathy of Undetermined Significance has a Kidney Problem. Journal of Onco-Nephrology, 2017, 1, 18-23.	0.6	3
333	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
334	An Unusual Case of Acute Myeloid Leukemia Cell Infiltration of the Renal Allograft: A Case Report and Review of Literature. Transplantation Proceedings, 2017, 49, 1578-1582.	0.6	2
335	Factors predicting organ response in light chain amyloidosis (AL).. Journal of Clinical Oncology, 2017, 35, 8048-8048.	1.6	1
336	Myeloma-Associated Glomerular Disease. , 2017, , 1-15.		0
337	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. Cancer, 2016, 122, 2197-2205.	4.1	37
338	Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplantation, 2016, 51, 1449-1455.	2.4	51
339	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, E348-52.	4.1	95
340	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
341	Light Chain Deposition Disease. , 2016, , 1-18.		0
342	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal, 2016, 6, e454-e454.	6.2	56

#	ARTICLE	IF	CITATIONS
343	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016, 6, e512-e512.	6.2	38
344	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	3.5	9
345	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.8	22
346	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	0.4	24
347	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1156-1158.	2.4	17
348	Laboratory testing in monoclonal gammopathy of renal significance (MGRS). <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 929-37.	2.3	35
349	Defining ultrahigh-risk AL amyloidosis with VWF. <i>Blood</i> , 2016, 128, 320-322.	1.4	2
350	Myelomatous Involvement of the Central Nervous System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 644-654.	0.4	38
351	Systemic Immunoglobulin Light Chain Amyloidosis—Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	3.0	43
352	What are the Newer Applications for Therapeutic Apheresis in Nephrology?. <i>Seminars in Dialysis</i> , 2016, 29, 350-353.	1.3	2
353	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. <i>American Journal of Hematology</i> , 2016, 91, 1123-1128.	4.1	76
354	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	4.1	57
355	Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 162-165.	2.5	7
356	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	4.1	71
357	Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2280-2287.	4.5	37
358	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1189-1211.	3.0	55
359	Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. <i>Kidney International</i> , 2016, 90, 658-664.	5.2	42
360	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	4.1	30

#	ARTICLE	IF	CITATIONS
361	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. <i>Leukemia</i> , 2016, 30, 1079-1085.	7.2	32
362	To biopsy or not to biopsy, that is the question in myeloma cast nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1-3.	0.7	62
363	A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1073-1082.	4.5	7
364	The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. <i>Kidney International</i> , 2016, 89, 897-908.	5.2	95
365	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e401-e401.	6.2	30
366	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
367	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.7	25
368	Monoclonal gammopathy: The good, the bad and the ugly. <i>Blood Reviews</i> , 2016, 30, 223-231.	5.7	54
369	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1278-1287.	6.1	210
370	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	1.4	1
371	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	1.4	4
372	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	1.4	2
373	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	1.4	1
374	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	1.4	3
375	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	1.4	5
376	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	1.4	1
377	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	1.4	0
378	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 996-996.	1.4	0

#	ARTICLE	IF	CITATIONS
379	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. Blood, 2016, 128, 3251-3251.	1.4	0
380	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. Blood, 2016, 128, 5480-5480.	1.4	1
381	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. Blood, 2016, 128, 3306-3306.	1.4	0
382	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. Blood, 2016, 128, 1194-1194.	1.4	0
383	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
384	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. Blood, 2016, 128, 3255-3255.	1.4	0
385	Outcome of Very Young (≤ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. Blood, 2016, 128, 5576-5576.	1.4	0
386	Urinary Exosomes Detect Amyloidogenic Light Chain in Patients Who Have Renal Progression Despite a Hematologic Complete Response. Blood, 2016, 128, 3268-3268.	1.4	0
387	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0
388	Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy. Clinical Nephrology, 2015, 83 (2015), 363-369.	0.7	24
389	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2015, 5, e296-e296.	6.2	90
390	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	1.3	36
391	Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum?. American Journal of Hematology, 2015, 90, 462-465.	4.1	3
392	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
393	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	5.2	339
394	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	3.0	92
395	Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2015, 90, 1054-1081.	3.0	106
396	Bortezomib-induced acute interstitial nephritis. Nephrology Dialysis Transplantation, 2015, 30, 1225-1229.	0.7	25

#	ARTICLE	IF	CITATIONS
397	Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy- and light-chain amyloidosis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1151-1155.	0.7	16
398	Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 130-136.	1.3	14
399	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. <i>Blood Cancer Journal</i> , 2015, 5, e310-e310.	6.2	62
400	Soluble suppression of tumorigenicity 2 (sTSG-2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	4.1	31
401	Lactate clearance and metabolic aspects of continuous high-volume hemofiltration. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 374-377.	2.9	22
402	The Authors Reply. <i>Kidney International</i> , 2015, 88, 202.	5.2	0
403	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015, 100, 1180-1188.	3.5	70
404	Dysproteinemias and Kidney Disease. , 2015, , 251-277.		0
405	Multiple myeloma after kidney transplantation. <i>Clinical Transplantation</i> , 2015, 29, 76-84.	1.6	17
406	Crystalglobulin-Induced Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 525-529.	6.1	58
407	Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. <i>Kidney International</i> , 2015, 87, 458-464.	5.2	91
408	The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease. <i>Kidney International</i> , 2015, 87, 692-697.	5.2	31
409	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	1.4	6
410	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	1.4	3
411	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	1.4	5
412	Recurrence of monoclonal IgA lambda glomerulonephritis in kidney allograft associated with multiple myeloma. <i>Clinical Nephrology</i> , 2015, 84 (2015), 241-246.	0.7	12
413	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	1.4	0
414	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	1.4	0

#	ARTICLE	IF	CITATIONS
415	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. Blood, 2015, 126, 5303-5303.	1.4	0
416	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Blood, 2015, 126, 3044-3044.	1.4	0
417	A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P.) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation, 2014, 29, 1570-1577.	0.7	92
418	Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney International, 2014, 86, 370-377.	5.2	82
419	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	4.1	4
420	Proliferative Glomerulonephritis Due to Monoclonal Deposition With Organized Substructures. American Journal of Kidney Diseases, 2014, 64, 994-998.	1.9	0
421	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	4.1	32
422	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart, 2014, 100, 383-388.	2.9	63
423	Use of Bortezomib in Heavy-Chain Deposition Disease: Report of 3 Cases. American Journal of Kidney Diseases, 2014, 64, 123-127.	1.9	15
424	Monoclonal Immunoglobulin Deposition Disease. , 2014, , 291-300.		1
425	Myeloma-related Kidney Disease. Advances in Chronic Kidney Disease, 2014, 21, 36-47.	1.4	50
426	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014, 28, 1122-1128.	7.2	1,128
427	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. European Journal of Haematology, 2014, 92, 485-490.	2.2	23
428	Impact of Molecular Adsorbent Recirculating System Therapy on Tacrolimus Elimination: A Case Report. Transplantation Proceedings, 2014, 46, 2440-2442.	0.6	9
429	Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Critical Care, 2014, 18, R110.	5.8	60
430	Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system. Liver Transplantation, 2014, 20, 867-868.	2.4	0
431	Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy. Mayo Clinic Proceedings, 2014, 89, 926-933.	3.0	240
432	Biopsy-Proven Acute Interstitial Nephritis, 1993-2011: A Case Series. American Journal of Kidney Diseases, 2014, 64, 558-566.	1.9	235

#	ARTICLE	IF	CITATIONS
433	Myeloma Cast Nephropathy. , 2014, , 257-263.		0
434	Hematologic Manifestations of Kidney Disease. Seminars in Hematology, 2013, 50, 207-215.	3.4	11
435	Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood, 2013, 122, 4172-4181.	1.4	70
436	The use of ⁹⁰ yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?. Leukemia and Lymphoma, 2013, 54, 2586-2587.	1.3	0
437	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	4.1	34
438	Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrology Dialysis Transplantation, 2013, 28, 137-146.	0.7	25
439	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
440	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	1.9	150
441	Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1857-1862.	4.5	101
442	Renal Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1515-1523.	4.5	212
443	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. Haematologica, 2013, 98, 988-992.	3.5	49
444	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney International, 2013, 83, 463-470.	5.2	101
445	Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplantation, 2013, 48, 1543-1547.	2.4	30
446	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	1.6	193
447	Laser Microdissection and Proteomic Analysis of Amyloidosis, Cryoglobulinemic GN, Fibrillary GN, and Immunotactoid Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 915-921.	4.5	80
448	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplantation, 2013, 48, 557-561.	2.4	158
449	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	1.6	147
450	Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013, 122, 68-73.	1.4	74

#	ARTICLE	IF	CITATIONS
451	How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 2013, 122, 3583-3590.	1.4	259
452	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2013, 122, 3095-3095.	1.4	1
453	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. Blood, 2013, 122, 3117-3117.	1.4	2
454	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. Blood, 2013, 122, 3119-3119.	1.4	3
455	Renal Disease In Patients With Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 5302-5302.	1.4	7
456	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. Blood, 2013, 122, 1979-1979.	1.4	0
457	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3209-3209.	1.4	0
458	Renal Monoclonal Immunoglobulin Deposition Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 231-239.	4.5	240
459	Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology, 2012, 30, 989-995.	1.6	837
460	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrology Dialysis Transplantation, 2012, 27, 1097-1101.	0.7	61
461	Laser microdissection and mass spectrometryâ€‘based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney International, 2012, 82, 226-234.	5.2	166
462	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathyâ€‘Related Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1964-1968.	4.5	72
463	Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrology Dialysis Transplantation, 2012, 27, 4137-4146.	0.7	109
464	Immunoglobulin D amyloidosis: a distinct entity. Blood, 2012, 119, 44-48.	1.4	17
465	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood, 2012, 119, 1117-1122.	1.4	78
466	How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood, 2012, 120, 3206-3213.	1.4	132
467	Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation. American Journal of Nephrology, 2012, 35, 365-371.	3.1	32
468	Effect of Continuous Venovenous Hemofiltration Dose on Achievement of Adequate Vancomycin Trough Concentrations. Antimicrobial Agents and Chemotherapy, 2012, 56, 6181-6185.	3.2	29

#	ARTICLE	IF	CITATIONS
469	Myeloma Kidney: Improving Clinical Outcomes?. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 342-351.	1.4	11
470	Current Approach to Diagnosis and Management of Acute Renal Failure in Myeloma Patients. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 297-302.	1.4	16
471	Novel approaches for reducing free light chains in patients with myeloma kidney. <i>Nature Reviews Nephrology</i> , 2012, 8, 234-243.	9.6	37
472	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. <i>Blood</i> , 2012, 120, 4292-4295.	1.4	447
473	The spectrum of monoclonal gammopathies affecting the kidney. <i>Leukemia and Lymphoma</i> , 2012, 53, 1656-1657.	1.3	4
474	Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL). <i>PLoS ONE</i> , 2012, 7, e38061.	2.5	36
475	Trends and outcomes of modern staging of solitary plasmacytoma of bone. <i>American Journal of Hematology</i> , 2012, 87, 647-651.	4.1	69
476	VEGF Inhibition, Hypertension, and Renal Toxicity. <i>Current Oncology Reports</i> , 2012, 14, 285-294.	4.0	187
477	Adenovirus-Induced Interstitial Nephritis Following Umbilical Cord Blood Transplant for Chronic Lymphocytic Leukemia. <i>American Journal of Kidney Diseases</i> , 2012, 59, 886-890.	1.9	16
478	Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. <i>American Journal of Kidney Diseases</i> , 2012, 59, 786-794.	1.9	174
479	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012, 118, 1585-1592.	4.1	106
480	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. <i>American Journal of Hematology</i> , 2012, 87, 51-54.	4.1	20
481	Treating myeloma cast nephropathy without treating myeloma. <i>Journal of Clinical Investigation</i> , 2012, 122, 1605-1608.	8.2	9
482	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. <i>Blood</i> , 2012, 120, 1858-1858.	1.4	2
483	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. <i>Blood</i> , 2012, 120, 3992-3992.	1.4	1
484	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	1.4	1
485	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	1.4	0
486	Refinement in Patient Selection to Reduce Treatment-Related Mortality From Stem Cell Transplantation in Amyloidosis. <i>Blood</i> , 2012, 120, 599-599.	1.4	0

#	ARTICLE	IF	CITATIONS
487	Imaging Evidence for Renomegaly in Patients with POEMS Syndrome. Academic Radiology, 2011, 18, 1241-1244.	2.5	2
488	Fibrillary Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 775-784.	4.5	177
489	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings, 2011, 86, 12-18.	3.0	164
490	Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. Journal of the American Society of Nephrology: JASN, 2011, 22, 1129-1136.	6.1	188
491	Myeloproliferative neoplasms cause glomerulopathy. Kidney International, 2011, 80, 753-759.	5.2	93
492	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplantation, 2011, 46, 970-975.	2.4	63
493	Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology, 2011, 64, 91-96.	1.2	59
494	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplantation, 2011, 46, 956-961.	2.4	16
495	Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. American Journal of Hematology, 2011, 86, 251-255.	4.1	78
496	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrology Dialysis Transplantation, 2011, 26, 2032-2036.	0.7	88
497	Protection against Malaria by MSP3 Candidate Vaccine. New England Journal of Medicine, 2011, 365, 1062-1064.	27.0	86
498	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 137-138.	3.0	4
499	Clinico-Pathological Conference on Acute Kidney Injury in a Patient with Nephrotic Syndrome. Nephron Clinical Practice, 2011, 119, c240-c247.	2.3	0
500	Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1009-1017.	4.5	133
501	Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange. New England Journal of Medicine, 2011, 364, 2365-2366.	27.0	98
502	Periodic fever syndrome with relapsing glomerulonephritis: a case report and teaching points. CKJ: Clinical Kidney Journal, 2011, 4, 346-351.	2.9	1
503	High-dose continuous venovenous hemofiltration combined with charcoal hemoperfusion for methotrexate removal. CKJ: Clinical Kidney Journal, 2011, 4, 87-89.	2.9	10
504	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	1.4	1

#	ARTICLE	IF	CITATIONS
505	The Timing of Acute Renal Failure Strongly Affects Survival of Immunoglobulin Light Chain (AL) Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation,. Blood, 2011, 118, 4120-4120.	1.4	5
506	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	1.4	8
507	IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.	1.4	0
508	Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury,. Blood, 2011, 118, 3949-3949.	1.4	0
509	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 2010, 116, 5126-5129.	1.4	146
510	Recurrence of Amyloidosis in a Kidney Transplant. American Journal of Kidney Diseases, 2010, 56, 394-398.	1.9	11
511	Coexistence of Myeloma Cast Nephropathy, Light Chain Deposition Disease, and Nonamyloid Fibrils in a Patient With Multiple Myeloma. American Journal of Kidney Diseases, 2010, 56, 971-976.	1.9	19
512	The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation, 2010, 10, 558-562.	4.7	20
513	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. American Journal of Hematology, 2010, 85, 431-434.	4.1	39
514	Discordance between serum cardiac biomarker and immunoglobulin free light chain response in patients with immunoglobulin light chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 2010, 85, 757-759.	4.1	111
515	Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvementâ€”A Prospective, Open-Label Pilot Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 445-453.	4.5	89
516	A case of bilateral renal arterial thrombosis associated with cryocryoglobulinaemia. CKJ: Clinical Kidney Journal, 2010, 3, 74-77.	2.9	17
517	Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrology Dialysis Transplantation, 2010, 25, 1340-1343.	0.7	43
518	Rituximab Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2188-2198.	4.5	247
519	Mass Spectrometryâ€”Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2180-2187.	4.5	109
520	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukemia and Lymphoma, 2010, 51, 2181-2187.	1.3	102
521	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	1.6	358
522	Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney International, 2010, 77, 721-728.	5.2	128

#	ARTICLE	IF	CITATIONS
523	Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 770-782.	4.5	156
524	Supportive Care for Amyloidosis. , 2010, , 65-75.		1
525	Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score. Blood, 2010, 116, 1892-1892.	1.4	2
526	Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicting Outcome In Over 400 Patients. Blood, 2010, 116, 3557-3557.	1.4	1
527	Evaluation of Low Dose Rasburicase In the Prevention of Renal Insufficiency and Dialysis After Chemotherapy. Blood, 2010, 116, 2574-2574.	1.4	0
528	Collection of Stem Cell Early In the Disease Course of Multiple Myeloma Is Associated with Early Engraftment.. Blood, 2010, 116, 4518-4518.	1.4	0
529	Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation.. Blood, 2010, 116, 3468-3468.	1.4	0
530	Trend towards Improved Day 100 and 2-Year Survival After SCT for AL Amyloidosis: Outcomes Before and After 2006. Blood, 2010, 116, 3554-3554.	1.4	13
531	Stem Cell Transplant without Growth Factor In Multiple Myeloma: Engraftment Kinetics, Bacteremia, and Hospitalization.. Blood, 2010, 116, 3469-3469.	1.4	0
532	Comparison of Troponin T and N-Terminal-Pro-Brain Natriuretic Peptides In Two Models of Treatment Related Mortality In AL Amyloidosis Patients Following Autologous Stem Cell Transplantation. Blood, 2010, 116, 3572-3572.	1.4	6
533	Large Sample of Nephrogenic Systemic Fibrosis Cases From a Single Institution. Archives of Dermatology, 2009, 145, 1095-102.	1.4	20
534	Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney International, 2009, 75, 420-427.	5.2	64
535	Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. CKJ: Clinical Kidney Journal, 2009, 2, 292-294.	2.9	2
536	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrology Dialysis Transplantation, 2009, 24, 3132-3137.	0.7	106
537	Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. CKJ: Clinical Kidney Journal, 2009, 2, 309-311.	2.9	9
538	Acute Kidney Injury in Patients with Inactive Cytochrome P450 Polymorphisms. Renal Failure, 2009, 31, 749-752.	2.1	12
539	Acquired Fanconi Syndrome After Treatment with Capecitabine, Irinotecan, and Bevacizumab. Annals of Pharmacotherapy, 2009, 43, 1370-1373.	1.9	13
540	Making the diagnosis of immunotactoid glomerulonephritis. Annals of Hematology, 2009, 88, 95-96.	1.8	1

#	ARTICLE	IF	CITATIONS
541	Acute cellular rejection in a renal allograft immediately following leukocyte engraftment after auto-SCT. Bone Marrow Transplantation, 2009, 43, 345-346.	2.4	7
542	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood, 2009, 113, 535-537.	1.4	61
543	A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement.. Blood, 2009, 114, 2797-2797.	1.4	4
544	Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis. PLoS ONE, 2009, 4, e5169.	2.5	72
545	Changes in Serum Free Light Chain Rather Than Intact Monoclonal Immunoglobulin Levels Predict Outcome with Therapy in Patients with Light Chain Amyloidosis.. Blood, 2009, 114, 747-747.	1.4	0
546	Detection of High Molecular Weight Light Chain Oligomers in Urinary Exosomes of Patients with AL Amyloidosis.. Blood, 2009, 114, 4886-4886.	1.4	3
547	Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia. Clinical and Experimental Nephrology, 2008, 12, 292-295.	1.6	22
548	Bleeding Complications After Transcutaneous Kidney Biopsy in Patients With Systemic Amyloidosis: Single-Center Experience in 101 Patients. American Journal of Kidney Diseases, 2008, 52, 1079-1083.	1.9	70
549	Induction of Heme Oxygenase-1 and Ferritin in the Kidney in Warm Antibody Hemolytic Anemia. American Journal of Kidney Diseases, 2008, 52, 972-977.	1.9	33
550	Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative. Mayo Clinic Proceedings, 2008, 83, 1131-1135.	3.0	90
551	Safety and Diagnostic Yield of Transjugular Renal Biopsy. Journal of Vascular and Interventional Radiology, 2008, 19, 546-551.	0.5	53
552	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. Mayo Clinic Proceedings, 2008, 83, 297-303.	3.0	39
553	Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney International, 2008, 73, 1282-1288.	5.2	171
554	Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clinical Chemistry and Laboratory Medicine, 2008, 46, 335-41.	2.3	22
555	Rituximab treatment of idiopathic membranous nephropathy. Kidney International, 2008, 73, 117-125.	5.2	219
556	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukemia and Lymphoma, 2008, 49, 36-41.	1.3	83
557	Approach to acute renal failure in biopsy proven myeloma cast nephropathy: Is there still a role for plasmapheresis?. Kidney International, 2008, 74, 956-961.	5.2	23
558	Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrology Dialysis Transplantation, 2008, 23, 2052-2057.	0.7	87

#	ARTICLE	IF	CITATIONS
559	Response to Rituximab in membranous nephropathy™. <i>Kidney International</i> , 2008, 74, 392.	5.2	0
560	Eprodisate slows the progression of renal disease in patients with AA amyloidosis. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 592-593.	2.0	2
561	Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. <i>Kidney International</i> , 2007, 71, 1296-1301.	5.2	100
562	Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 440-444.	4.5	38
563	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. <i>Haematologica</i> , 2007, 92, 1415-1418.	3.5	114
564	Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. <i>American Journal of Hematology</i> , 2007, 82, 409-413.	4.1	22
565	Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2007, 109, 2291-2298.	4.1	145
566	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 605-611.	2.4	57
567	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). <i>Bone Marrow Transplantation</i> , 2007, 40, 989-993.	2.4	10
568	Renal Manifestations of Plasma Cell Disorders. <i>American Journal of Kidney Diseases</i> , 2007, 50, 155-165.	1.9	34
569	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. <i>Blood</i> , 2007, 110, 4779-4779.	1.4	0
570	Should Troponin Level Be an Exclusion Criterion for Stem Cell Transplantation in Primary Amyloidosis?.. <i>Blood</i> , 2007, 110, 3003-3003.	1.4	0
571	Plasma Exchange in Multiple Myeloma. <i>Annals of Internal Medicine</i> , 2006, 144, 455.	3.9	5
572	Nephrogenic fibrosing dermopathy: lessons from the past. <i>International Journal of Dermatology</i> , 2006, 45, 639-641.	1.0	11
573	A Proliferative Glomerulonephritis Secondary to a Monoclonal IgA. <i>American Journal of Kidney Diseases</i> , 2006, 47, 342-349.	1.9	32
574	Changing Incidence of Glomerular Disease in Olmsted County, Minnesota. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 483-487.	4.5	212
575	Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy. <i>Annals of Internal Medicine</i> , 2006, 145, 234.	3.9	113
576	Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL).. <i>Blood</i> , 2006, 108, 5125-5125.	1.4	0

#	ARTICLE	IF	CITATIONS
577	Risk Factors of Treatment Related Mortality during Autologous Stem Cell Transplant in Patients with Light Chain Associated Amyloidosis (AL).. Blood, 2006, 108, 3082-3082.	1.4	0
578	Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood, 2005, 106, 3353-3357.	1.4	44
579	Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement. Kidney International, 2005, 68, 1464-1471.	5.2	11
580	Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. American Journal of Kidney Diseases, 2005, 45, 102-111.	1.9	34
581	Renal Response After High-Dose Melphalan and Stem Cell Transplantation Is a Favorable Marker in Patients With Primary Systemic Amyloidosis. American Journal of Kidney Diseases, 2005, 46, 270-277.	1.9	74
582	Living Donor Kidney and Autologous Stem Cell Transplantation for Primary Systemic Amyloidosis (AL) with Predominant Renal Involvement. American Journal of Transplantation, 2005, 5, 1660-1670.	4.7	83
583	Acute Granulomatous Interstitial Nephritis Secondary to Bisphosphonate Alendronate Sodium. Renal Failure, 2005, 27, 485-489.	2.1	17
584	Recurrent Goodpasture's disease secondary to a monoclonal IgA1- κ antibody autoreactive with the $\alpha 1(\pm 1/\pm 2)$ chains of type IV collagen. American Journal of Kidney Diseases, 2005, 45, 397-406.	1.9	74
585	Wegener's granulomatosis presenting as multiple bilateral renal masses. Nephrology Dialysis Transplantation, 2004, 19, 984-987.	0.7	18
586	Long-term outcome of renal transplantation in light-chain deposition disease. American Journal of Kidney Diseases, 2004, 43, 147-153.	1.9	187
587	Acute renal failure after liver transplantation: The role of dopamine and fenoldopam. Liver Transplantation, 2004, 10, 993-994.	2.4	4
588	Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose Therapy and Stem Cell Transplantation in Patients with Primary Amyloidosis.. Blood, 2004, 104, 937-937.	1.4	1
589	A tale of two markers. Liver Transplantation, 2002, 8, 600-602.	2.4	8
590	Chronic renal dysfunction late after liver transplantation. Liver Transplantation, 2002, 8, 916-921.	2.4	134
591	Acute cholestatic liver disease protects against glycerol-induced acute renal failure in the rat. Kidney International, 2001, 60, 1047-1057.	5.2	51
592	Chronic lymphocytic leukemia and light chain proximal tubulopathy: A rare presentation of a common disease. Journal of Onco-Nephrology, 0, , 239936932210796.	0.6	1
593	Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. Frontiers in Endocrinology, 0, 13, .	3.5	0